Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2012
10/18/2012US20120264804 T type calcium channel blockers and the treatment of diseases
10/18/2012US20120264803 Method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients
10/18/2012US20120264800 Kinase inhibitors and method of treating cancer
10/18/2012US20120264798 Prodrugs of inhibitors of plasma kallikrein
10/18/2012US20120264797 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
10/18/2012US20120264795 Combination therapy with parp inhibitors
10/18/2012US20120264794 Method for Preparing Largazole Analogs and Uses Thereof
10/18/2012US20120264792 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases
10/18/2012US20120264790 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals
10/18/2012US20120264789 Polymorphs of sorafenib acid addition salts
10/18/2012US20120264785 Fluoro-substituted 3,5-dicyano-4-(1H-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof
10/18/2012US20120264771 Method for Treating Androgen Receptor Positive Cancers
10/18/2012US20120264770 Hsp90 inhibitors
10/18/2012US20120264769 Methanocarba adenosine derivatives and dendrimer conjugates thereof
10/18/2012US20120264768 Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
10/18/2012US20120264766 Pseudobase benzo[c]phenantridines with improved efficacy, stability and safety
10/18/2012US20120264764 Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use
10/18/2012US20120264763 Indoline Anti-Cancer Agents
10/18/2012US20120264759 Benzyl substituted triazine derivatives and their therapeutical applications
10/18/2012US20120264756 Phosphatidylcholine Transfer Protein Inhibitors
10/18/2012US20120264755 Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase
10/18/2012US20120264751 Pyrrolopyrazoles, potent kinase inhibitors
10/18/2012US20120264747 Triazolopyridine jak inhibitor compounds and methods
10/18/2012US20120264746 Cell migration modulating compounds
10/18/2012US20120264744 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof
10/18/2012US20120264740 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
10/18/2012US20120264739 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
10/18/2012US20120264738 Dispiropyrrolidine derivatives
10/18/2012US20120264737 Heterocyclic Modulators of Lipid Synthesis
10/18/2012US20120264735 Tyrosine kinase inhibitors
10/18/2012US20120264734 Aryl- or Heteroaryl-Substituted Benzene Compounds
10/18/2012US20120264732 Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264731 Chromenone derivatives
10/18/2012US20120264730 Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264725 Substituted porphyrins
10/18/2012US20120264720 Identification and treatment of cancer subsets
10/18/2012US20120264716 Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264715 Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
10/18/2012US20120264710 Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
10/18/2012US20120264704 Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors
10/18/2012US20120264697 Uses of hypoxia-inducible factor inhibitors
10/18/2012US20120264693 Compounds acting as peptide gap junction modulators, and uses thereof
10/18/2012US20120264676 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
10/18/2012US20120264675 Cmv gene products promote cancer stem cell growth
10/18/2012US20120264674 Methods for preparing purified polypeptide compositions
10/18/2012US20120264625 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
10/18/2012US20120263806 Uses of North American Ginseng Fractions for Treating Leukemia
10/18/2012US20120263802 Use of Quinazoline Derivative ZD6474 Combined With Platinum Compounds and Optionally Ionising Radiation in the Treatment of Diseases Associated With Angiogenesis and/or Increased Vascular Permeability
10/18/2012US20120263797 Implantable polymer for bone and vascular lesions
10/18/2012US20120263783 Single molecule nucleic acid nanoparticles
10/18/2012US20120263780 Carbohydrate Entrapped Active Agent Delivery Composition and Articles Using the Same
10/18/2012US20120263765 Agents from cells
10/18/2012US20120263759 Coating Comprising An Elastin-Based Copolymer
10/18/2012US20120263757 Composition and method for diagnosis and immunotherapy of prostate cancer
10/18/2012US20120263754 Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
10/18/2012US20120263749 Polyvalent conjugate vaccine for cancer
10/18/2012US20120263748 Superior Molecular Vaccine Linking the Translocation Domain of a Bacterial Toxin to an Antigen
10/18/2012US20120263747 Albumin-Fused Anti-Angiogenesis Peptides
10/18/2012US20120263739 Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
10/18/2012US20120263738 Multiplex dicer substrate rna interference molecules having joining sequences
10/18/2012US20120263735 Synthetic immunogenic glycoconjugate for melanoma immunotherapy
10/18/2012US20120263732 Cd40 antibody formulation and methods
10/18/2012US20120263730 Receptors of rspo2 and rspo3
10/18/2012US20120263723 c-Met Antibodies
10/18/2012US20120263722 Dual Variable Domain Immunoglobulins and Uses Thereof
10/18/2012US20120263721 Therapeutic Combination and Methods of Treatment With a DLL4 Antagonist and an Anti-Hypertensive Agent
10/18/2012US20120263717 Humanized anti-fgf19 antagonists and methods using same
10/18/2012US20120263716 Method of treating cancers and a pharmaceutical composition that may be used in practicing said method
10/18/2012US20120263714 Substituted halophenoxybenzamide derivatives
10/18/2012US20120263713 Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone
10/18/2012US20120263712 Pyrrolidine-1,2-dicarboxamide derivatives
10/18/2012US20120263711 Engineering Fc Antibody Regions to Confer Effector Function
10/18/2012US20120263708 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
10/18/2012US20120263707 Broad Spectrum ErbB Ligand Binding Molecules and Methods for Preparing and Using Them
10/18/2012US20120263706 Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
10/18/2012US20120263702 Human Aminoacyl-tRNA Synthetase Polypeptides Useful For The Regulation of Angiogenesis
10/18/2012US20120263693 Methods for Treating Progressive Multifocal Leukoencephalopathy (PML)
10/18/2012US20120263691 Modular aptamer-regulated ribozymes
10/18/2012US20120263685 Anti-tumor composition comprising human-derived adult stem cells
10/18/2012US20120263679 Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof
10/18/2012US20120263677 Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
10/18/2012US20120263676 Compositions, methods and kits relating to her-2 cleavage
10/18/2012US20120263675 Bivalent diazo bicyclic smac
10/18/2012US20120263654 Melanoma specific biomarker
10/18/2012US20120263653 Methods and systems for generating nanoparticles
10/18/2012US20120263651 Single Stranded DNA Aptamers Binding NF-kB/RelA
10/18/2012US20120263650 Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
10/18/2012US20120263648 Rna nanoparticles and nanotubes
10/18/2012US20120263647 Pro104 Antibody Compositions and Methods of Use
10/18/2012US20120263645 Radiolabeled compound directable in vivo to target tissue and use thereof
10/18/2012DE102011016875A1 Zubereitung enthaltend DISC1 und/oder mindestens ein DISC1-Fragment zur Anwendung bei der therapeutischen Behandlung des menschlichen oder tierischen Körpers Preparation comprising DISC1 and / or at least one DISC1 fragment for use in the therapeutic treatment of the human or animal body
10/18/2012CA2836299A1 Clonal strains of attenuated vaccinia viruses and methods of use thereof
10/18/2012CA2833180A1 Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists
10/18/2012CA2833171A1 Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
10/18/2012CA2833147A1 Anti- il-1r1 inhibitors for use in cancer
10/18/2012CA2832972A1 Antisense modulation of ptp1b expression
10/18/2012CA2832846A1 Substituted benzene compounds
10/18/2012CA2832843A1 Aryl-or heteroaryl-substituted benzene compounds
10/18/2012CA2832787A1 Chromenone compounds as pi 3 - kinase inhibitors for the treatment of cancer
10/18/2012CA2832704A1 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
1 ... 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 ... 2211